The summary of product characteristics states that lixisenatide (Lyxumia) is licensed for treating adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Lixisenatide is administered as a once-daily subcutaneous injection using a fixed-dose pen device. The summary of product characteristics states that dosing is initiated at 10 micrograms once daily for 14 days, followed by a maintenance dose of 20 micrograms once daily thereafter. The dose should be administered within the hour before the first meal of the day or the evening meal.
A 2-pen pack (28 days' supply) costs £54.14, with flat pricing across initiation and maintenance doses (cost taken from MIMS July 2013 and excluding VAT).